Global Programme to Eliminate Lymphatic Filariasis ... - libdoc.who.int

More documents

Recommendations

Info

62Figure 3.63 Outcomes and planning 2000-2006Figure 3.64 LF at-risk populationAnnual Report on Lymphatic Filariasis 2003No. of IUs12963No. IUs0.80.70.60.50.40.30.20.1million peoplePopulation in millions10 Total pop.9 M08642At-risk pop.1.5 MChapter 3 Programme implementation0% of at-risk population covered200210020032004Planned pop. coverage7550259.420052006Figure 3.65 Geographical coverage20070.0Pop. reported to haveingested drugs22Figure 3.66 MDA reported coverage%1009084807570600200220035020022003Figure 3.67 IUs with reported coverage >65%Figure 3.68 Updated mapping status1008092.3Total: 163 IUs16 IUs 134 IUs 13 IUsUncertain Non-endemic Endemic6060%4020020022003
GUYANA63Endemicity statusEndemicNon-endemicUncertainAnnual Report on Lymphatic Filariasis 2003LF is a major public health problem in Guyana. Mappingwas completed in 2001. The estimated at-risk populationis 639 000 people — 90% of the entire population. Theproportion of infected population is 9.3%.The country is divided into 10 administrative regions. Theregion was designated as the IU. Nine of the 10 regions(IUs) are considered endemic for LF. Surveys conductedin 2002 revealed that approximately 0.5% of the total populationhas lymphoedema and 0.1% hydrocele. Two fixedsentinel sites and two spot check sites were establishedin 2003. Baseline ICT prevalence was 35% in the sentinelsite of Georgetown and 18% in that of New Amsterdam.The ministry of health authorities decided to adopt thediethylcarbamazine-fortified salt (DEC-fortified salt)treatment regimen and the importation of DEC-fortifiedsalt was therefore approved by the National Cabinet andthe Food and Drug Department in 2002. Importation ofthe DEC-fortified salt, which is supplied by three companies(from Cuba, Jamaica and Trinidad) commencedin June 2003. The supplies from Cuba and Trinidad andTobago were not guaranteed; only Jamaica has beenexporting fortified salt and some problems occurreddue to the change of staining of the product. The officialprogramme launch was in July 2003 and was limited toGeorgetown. It is expected to cover the entire countrywithin the next year. A monitoring and evaluation planhas been developed to evaluate salt use at the householdlevel. Implementation of this plan will take place in 2004.A quality control system to monitor the salt fortificationprocess was in place prior to the 2003 launch. Allimported salt is tested by the Food and Drug Departmentwith confirmatory testing by CDC.Chapter 3 Programme implementationTable 3.13 Goal: to eliminate LF from Guyana by 2006Objectives• To implement DEC-fortified salt MDAregimen in conjunction with disabilitymanagement activities• To decrease suffering from, andworsening of, LF-related disability• To integrate the LF elimination programmeinto ongoing communityhealth worker activitiesStrategies• Establish salt association to strengthen private sector partnership• Promote and sustain population support through social marketing andmobilization• Establish disability clinics in all regions, in coordination with existingdermatology/leprosy mobile clinics• Continue health worker training
Page 1 and 2:
For further information about lymph
Page 3:
WHO/CDS/CPE/CEE/2005.52GlobalProgra
Page 7 and 8:
3Report of the Technical Advisory G
Page 9 and 10:
P R O G R A M M E H I G H L I G H T
Page 11:
I N T R O D U C T I O N7This Annual
Page 14 and 15:
10Annual Report on Lymphatic Filari
Page 16 and 17: 12Annual Report on Lymphatic Filari
Page 42 and 43: 38Figure 3.2 Outcomes and planning
Page 59 and 60: UNITED REPUBLIC OF TANZANIA55Endemi
Page 61 and 62: ZANZIBAR, UNITED REPUBLIC OF TANZAN
Page 63: 59AMERICAN PROGRAMME REVIEWGROUPAt
Page 86 and 87: 82Figure 3.100 Outcomes and plannin
Page 104 and 105: 100Annual Report on Lymphatic Filar
Page 116 and 117:
112Annual Report on Lymphatic Filar
Page 118 and 119:
114Figure 3.196 Outcomes and planni
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 127:
C H A P T E R 6FURTHER DOCUMENTATIO
Page 130 and 131:
Page 132 and 133:
Page 135 and 136:
ANNUAL REPORT FOR THE NATIONAL PROG
Page 137 and 138:
1332. PROGRAMME RESOURCES2.1 Please
Page 139 and 140:
1353.3 Interruption of transmission
Page 141 and 142:
1373.3.6a Report of MDA coverage by
Page 143 and 144:
1393.3.7 Surveys in sentinel sites
Page 145 and 146:
1413.3.10 Please attach a map of th
Page 147 and 148:
1434. SERIOUS ADVERSE EXPERIENCES (
Page 149 and 150:
A N N E X E SANNEX 3: LIST OF LF-EN
Page 151 and 152:
147RAPLOARPRGSAESEAROTAG-LFTDRUNDPU
Page 153 and 154:
149Drug administration and monitori
show all

Global Programme to Eliminate Lymphatic Filariasis ... - libdoc.who.int

Create successful ePaper yourself

Delete template?

Save as template?